key: cord-0074132-gci6k8hg authors: Mohamed Hussein, Aliae A. R.; Ibrahim, Islam H.; Mahmoud, Islam A.; Amary, Marwa; Sayad, Reem title: To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review date: 2022-01-28 journal: Egypt J Bronchol DOI: 10.1186/s43168-021-00109-3 sha: ffa3b791ad4cf0a1fb1090229fd3280f449e085a doc_id: 74132 cord_uid: gci6k8hg Until now, there are more than two hundred million confirmed cases of COVID-19 including more than seven million deaths. Clinical trials of all three vaccines authorized for use in the UK (Pfizer–BioNTech, Oxford–AstraZeneca, and Moderna) have reported high vaccine efficacy. This rapid systematic review was initiated because no systematic review had been conducted to determine the safety and efficacy of AstraZeneca ChAdOx1 nCoV-19 vaccine. Evidence acquisition: A systematic search in the following platforms: PubMed, Google Scholar, Scopus, WOS, and MEDLINE databases for all articles in the English language regarding safety and efficacy of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 was performed. Papers published up to end of June were included. Evidence synthesis: Out of 477 retrieved articles, fifteen are included. All the selected articles are concerned with evaluation of AstraZeneca ChAdOx1 nCoV-19 vaccine. Three of them discussed the effectiveness of ChAdOx1 nCoV-19 vaccine, while thirteen (one is common with the group of the effectiveness) measured the adverse effects associated with the vaccine. Because thrombosis was recorded as a serious adverse effect developed after ChAdOx1 nCoV-19 vaccination, it was emphasized in a special group to be analyzed separately. In conclusion: the main message of selected papers was that the value of ChAdOx1 nCoV-19 vaccination to provide critical protection should be considered higher compared to the significant worldwide burden of the emerging COVID-19 infection. No causal relations were found to link cases- having thrombotic adverse reactions to the vaccine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43168-021-00109-3. In early December 2019, the Chinese Center of Disease Control reported that SARS-CoV-2 infection is the cause of the outbreak that started in Wuhan City [1] . SARS-CoV-2 virus is the third member of coronaviruses that causes epidemics in human history following SARS-COV and MERS. It is highly infectious and can spread globally and rapidly [2] . Until now, there are more than two hundred million confirmed cases of COVID-19 including more than seven million deaths [3] . Vaccines mimic the virus-or part of the virus-so they can protect against stimulation of the immune system to produce antibodies. Their safety standards must be higher than other medicines as they are used for the prevention of infectious diseases in healthy people and reduction of morbidity and mortality without long-lasting effects [4, 5] . For that reason, scientists are in a race with time to discover new vaccines against COVID-19. There are more than 170 candidate vaccines that are now being followed up by the World Health Organization (WHO) [6] . The first COVID-19 vaccines were approved shortly after The Egyptian Journal of Bronchology the initial phase 3 safety and efficacy studies [7] . Clinical trials of all three vaccines authorized for use in the UK (Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna) have reported high vaccine efficacy [8] [9] [10] . Large post-licensing epidemiological studies are needed to complement the results of pre-licensing trials to estimate the efficacy of these vaccines at the population level in real-world conditions, because vaccine development normally takes a very long period to confirm that vaccines are safe and effective before they are used. This rapid systematic review was initiated because no systematic review had been conducted to determine the safety and efficacy of AstraZeneca ChAdOx1 nCoV-19 vaccine especially after publishing a number of case series which revealed serious adverse effects associated with the vaccine such as life-threatening thrombocytopenic thrombosis. The study was designed as a systematic review according to PRISMA guidelines [11] . All steps of this study were pre-specified, and the protocol was registered on Clini caltr ial. gov: NCT05060861. On May 22, 2021, we searched PubMed, Google Scholar, Scopus, WOS, and MEDLINE databases for all articles in English regarding the safety and efficacy of the SARS-CoV-2 vaccine ChAdOx1 nCoV-19. The search strategy can be retrieved in supplementary digital material 1. Materials available as gray literature were followed and searched in pre-print platforms (MedRxiv, BoiRxiv), protocols, WHO reports, conference posters, thesis, or trial registers in Clini calTr ial. gov. Two authors (I.A.M and M.A) independently completed all searches and removed all duplicate records. We selected the articles based on titles and abstracts. The second and last screening stage was performed by two authors (I.A.M and M.A), and discrepancies and doubts were solved by a consensus with two more authors (R.S, I.H.I). We critically appraised the full text of each study that was included if respected one of the following inclusion criteria: (1) P: volunteers (aged 18 years old or more), (2) I: ChAdOx1 nCoV-19 vaccine, (3) C: any comparator vaccine 4) O: Efficacy and Safety, (5) study design: Randomized controlled trials, retrospective studies, cohort, case-control, case series, survey, and recommendation, (6) Language: only English A data extraction form was created in word. Data were extracted by three authors (R.S., I.A.M. and M.A.) comprising the following data (if applicable): (1) study name (author/year), (2) study design, (3) study period, (4) setting (institute, city, and country), (5) study protocol number, (6) aim of study, (7) main and secondary outcome, (8) target population, (9) main age of study population, (10) classification of population according to gender, (11) sample size, (12) dose, (13) method of evaluation, and (14) conclusion We did not appraise the quality of included studies due to urgency and need of rapid appraisal of published data in this topic. The statistical analysis was performed using open meta-analyst software [12] [13] [14] . Dichotomous and continuous data were pooled as untransformed proportion (PR) and standardized mean difference (SMD), respectively, in a random-effects model with 95% confidence interval (CI). Heterogeneity was assessed by observation of the graphs on forest plots and measured by chi-square test and I-square tests for the degree of the heterogeneity. Between studies, significant heterogeneity was defined as a chisquare test with p<0.1 and I 2 tests >50% [15] . We considered the endpoints statistically significant with p value <0.05. Irrespective of the between-study heterogeneity, subgroup analysis was done for all efficacy endpoints based on the method by which the efficacy was measured in the included studies, and the adverse events were measured depending on the number of cases developed these adverse events after vaccination. Out of 477 retrieved articles, fifteen are included [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Figure 1 provides all details about the study selection process. All the selected articles are concerned with the evaluation of the AstraZeneca ChAdOx1 nCoV-19 vaccine. Three of them are concerned with the effectiveness of the ChAdOx1 nCoV-19 vaccine [18, 23, 29] , while thirteen (one is common with the group of the effectiveness) consider the adverse effects associated with the vaccine [16, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 30] . Because thrombosis is a serious adverse effect developed after ChAdOx1 nCoV-19 vaccination, it was placed in a special group to be analyzed separately [16, 20, [24] [25] [26] [27] [28] 30] ( Table 1) . (Fig. 4) . Seven studies reported the safety of the ChAdOx1 nCoV-19 vaccine. A total of 635,109 persons received the 1st dose and responded to safety evaluation so This investigation involved a systematic review and metaanalysis of RCTs, cohorts, case series, case reports, casecontrol, and cross-sectional studies to summarize the efficacy and safety of the ChAdOx1 nCoV-19 vaccine. This investigation comprised 9 cohorts, 2 case reports, 1 RCTs, 1 case series, 1 case-control, and 1 cross-sectional study with a total sample size of 1,368,188 patients, 107,8284 of them were analyzed to evaluate the efficacy, and 635,184 were analyzed to evaluate the safety, with 345,280 common between two groups. The study findings revealed that the first doses of the ChAdOx1 vaccines were associated with protection against COVID-19 admission to hospital and a decrease in the number of positive cases among the vaccinated population. A vaccine effect of 78% for protection against hospitalization and 63.7% for decreasing in the number of +ve cases among the vaccinated population. In the elderly age group, based on a pooled analysis for the vaccine, we observed vaccine efficiency of 78.3%. The most reported systemic adverse effects associated with ChAdOx1 vaccine are malaise (75.20%), headache (23.86%), fatigue (22.39%), vomiting (21.06%), chills (15.80%), joint pain (12.30%), fever (9.08%), muscle pain (8.48%), nausea (5.84%), diarrhea (2.58%), and bleeding (0.02%). The percentage of older people with at least one adverse event (22.7%) is larger than the percentage of younger people with at least one adverse event (21.13%). Cases with thrombotic adverse events had mean platelet count = 39.873 × 10 9/L , (lower than normal mean) and Activated partial thromboplastin time (aPTT) = 29.943 s (within normal value). Despite these values, thrombosis also occurred. However, the recorded INR peak was 1.271, this value is lower than normal range and this may stimulate thrombosis formation. The fibrinogen level was1.444 g/l, and D-dimer 33.047 mg/l. The most reported thrombotic adverse events were deep venous thrombosis (77 cases), thrombosis in other organs/areas (57 cases), cerebral venous sinus thrombosis (46 cases), pulmonary embolism (23 cases), and splanchnic vein thrombosis (23 cases). The increasing number of reports on rare thrombotic events after SARS-CoV-2 vaccination draw public attention and led to concerns regarding the safety of this vaccine due to the uncertainty of the origin of these undesired reactions The limitations of this study include the small number of potential thrombotic adverse events which were contained from case reports and case series but it shouldn't be neglected because these are serious adverse events that lead to death. The quality of the included studies was not evaluated to decide the importance of the included data, due to lack of time during the pandemic. However, this study has provided valuable information about the safety and efficacy of the ChAdOx1 vaccine from trusted databases with a large sample size and summarizes all the literature which is published until the time of searching. Finally, the observed clinical and laboratory features of the VITT are exceptional and rare and the reported side effects cannot lead to death mostly and are relieved by medical treatment except in a few cases. Therefore, the value of COVID-19 vaccination to provide critical protection should be considered higher compared to the significant health risk of COVID-19. With the better recognition of this rare complication and the availability of efficient therapies, the risk-benefit ratio of ChAdOx1 nCoV-19 might be reconsidered further. All selected articles are based on published literature about the viral vector COVID-19 vaccine "ChAdOx1 nCoV-19. " The main message is that the value of COVID-19 vaccination ChAdOx1 nCoV-19 to provide critical protection should be considered higher compared to the significant health risk of COVID-19. Further updates are needed to follow the emerging vaccines and recognize their safety and efficacy against different variants of the novel virus Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle Clinical features of patients infected with 2019 novel coronavirus in Wuhan Dashboard| WHO Coronavirus (COVID-19) Dashboard with Vaccination Data The future of vaccines, immunization concepts and practice Advances in mRNA vaccines for infectious diseases Covid vaccine tracker: when will a coronavirus vaccine be ready? The Guardian Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Cumulative meta-analysis of therapeutic trials for myocardial infarction Conducting meta-analyses in R with the metafor package Closing the gap between methodologists and end-users: R as a computational back-end Measuring inconsistency in meta-analyses Antibodymediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Adverse events following immunization associated with coronavirus disease 2019 vaccination reported in the mobile vaccine adverse events reporting system Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination Prothrombotic immune thrombocytopenia after COVID-19 vaccine Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study Thrombocytopenia and intracranial venous sinus thrombosis after "COVID-19 vaccine AstraZeneca" exposure Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s43168-021-00109-3. A AA Mohamed Hussein was the team leader, responsible for checking the validity of the study, follow up all steps, writing, and editing; I Hussein, I Mahmoud, and M Amary were responsible for database searching, examination of records, full-text assessment; R Alsayad was the student leader, examined eligible studies, and performed the qualitative synthesis. All authors have read and approved the final version of the study. The authors did not receive funds for the accomplishment of this study. Data are available in the supplementary file. The study was approved by the ethical committee Assist Faculty of Medicine. The authors declare that they have no competing interests.